Andhra Pradesh High Court (HC) has approved the deal between Aurobindo Pharma and its wholly-owned subsidiary Curepro Parenterals. Under the Scheme of Arrangement, Aurobindo would transfer its injectables Unit IV to Curepro, and the same is to be effective from April 1, 2014.
The company will take necessary steps to make the scheme effective and intimate the exchanges accordingly.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
